(Q46792873)

English

Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma

scientific article published on 27 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Comparison of various criteria in interpreting end of therapy F-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography in patients with aggressive non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

1 reference

based on heuristic

inferred from title

author name string

Kuruva Manohar

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Bhagwant Rai Mittal

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Senthil Raja

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Anish Bhattacharya

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Pankaj Malhotra

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Subhash Varma

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

publication date

27 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

54

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

714-719

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Dual-modality imaging of function and physiology

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

FDG-PET/CT in re-staging of patients with lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

PET and restaging of malignant lymphoma including residual masses and relapse

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

PET imaging for response assessment in lymphoma: potential and limitations

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Rituximab: mechanism of action

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Standards for PET image acquisition and quantitative data analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.717693

21 January 2018

Identifiers

10.3109/10428194.2012.717693

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

release_nihpdswvozerxf4645cdtzctvy

1 reference

https://api.fatcat.wiki/v0/release/nihpdswvozerxf4645cdtzctvy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/22870929

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46792873&oldid=2132268253"